Latest Headlines

Latest Headlines

AstraZeneca and Daiichi Sankyo field backlash over Super Bowl OIC awareness ad

A parade of politicians, physicians and pundits have criticized a Super Bowl commercial intended to stimulate awareness of opioid-induced constipation, linking the campaign to the opioid prescription drug addiction problem in the U.S. and forcing AstraZeneca and Daiichi Sankyo, which market the OIC relief drug Movantik, to defend it.

AstraZeneca, Innate Pharma wrap up rollout of first wave of checkpoint inhibitor trials

AstraZeneca has kicked off another clinical trial of monalizumab, bringing to an end a rollout of studies it committed to when it struck its $1.3 billion (€1.1 billion) alliance with Innate Pharma. The fifth and final clinical trial in the first wave of studies is investigating the combination of monalizumab and AstraZeneca's big immuno-oncology hope durvalumab.

AstraZeneca's cancer checkpoint combo looks promising in small lung cancer study

AstraZeneca has successfully wrapped a small proof-of-concept study to help demonstrate how two immunotherapy drugs will likely work better than one. The pharma giant is reporting that a combination of the PD-L1 drug durvalumab combined with the CTLA-4 treatment tremelimumab achieved an objective tumor response rate of 23% for metastatic non-small cell lung cancer patients.

China pulls through for AstraZeneca again, roxadustat in focus

China once again aided AstraZeneca, with the full-year sales up 15%, the same pace as Latin America, and up 10% on the fourth quarter.

AstraZeneca CEO still interested in M&A but he is getting very picky

AstraZeneca recently plunked down $575 million to get from Takeda global rights to the chronic obstructive pulmonary disease treatment Daxas. It was the kind of deal that currently intrigues CEO Pascal Soriot, something that will immediately pay off and which falls into one of the three areas around which he is trying to rebuild the company.

Patent losses looming, AZ fights back with Brilinta, diabetes and China

AstraZeneca is suffering from a new round of patent losses, and that suffering will only worsen. Already hurting from generic competition to its former top-seller, Nexium, the London-based company will fall off another patent cliff this year--Crestor--and faces still another in Seroquel XR next year.

AstraZeneca taps CRISPR to extract value from genome data

AstraZeneca has outlined how it is using the white-hot CRISPR genome editing technology to put its repositories of sequencing data to work in its R&D programs. The initiative is one of the many ways in which AstraZeneca is applying the technology at its drug discovery and development units.

Allergan links with AstraZeneca on new antibiotic treatment

As it prepares to be subsumed in the $160 billion merger deal with Pfizer, Ireland's Allergan is not backing away from making deals. The company unveiled a three-way pact with AstraZeneca this morning to develop a new antibiotic with the help of a U.S. government agency.

Pfizer, GSK, AZ and BMS join digital drug design drive to weed out nonviable molecules

A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.

GSK, AstraZeneca and J&J back $57M effort to springboard university drug research

Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at spinning out new therapies into the global pipeline.